These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 8859286

  • 1. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique.
    Lowe NJ, Maxwell A, Harper H.
    J Am Acad Dermatol; 1996 Oct; 35(4):569-72. PubMed ID: 8859286
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Botulinum toxin type A injection for the treatment of frown lines.
    Song KH.
    Ann Pharmacother; 1998 Dec; 32(12):1365-7. PubMed ID: 9876820
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA, Fallico N, Mazzocchi M, Scuderi N.
    Am J Clin Dermatol; 2011 Dec 01; 12(6):377-88. PubMed ID: 21877763
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y, Fang F, Lai W, Li C, Li L, Liu Q, Lu J, Pang X, Sun J, Shi X, Picaut P, Prygova I, Andriopoulos B, Sun Q.
    Aesthetic Plast Surg; 2023 Feb 01; 47(1):351-364. PubMed ID: 36536093
    [Abstract] [Full Text] [Related]

  • 8. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V, Solish N, Kaufman-Janette J, Yoelin S, Shamban A, Schlessinger J, Snyder D, Gallagher C, Liu Y, Shears G, Rubio RG.
    J Am Acad Dermatol; 2020 Apr 01; 82(4):838-845. PubMed ID: 31791824
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dilution, storage, and electromyographic guidance in the use of botulinum toxins.
    Mantell AM.
    Dermatol Clin; 2004 Apr 01; 22(2):135-6, v. PubMed ID: 15222572
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D.
    J Cosmet Laser Ther; 2002 Mar 01; 4(1):15-8. PubMed ID: 12079632
    [Abstract] [Full Text] [Related]

  • 12. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
    Lowe NJ, Shah A, Lowe PL, Patnaik R.
    J Cosmet Laser Ther; 2010 Apr 01; 12(2):106-11. PubMed ID: 20151785
    [Abstract] [Full Text] [Related]

  • 13. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, Botox Glabellar Lines II Study Group.
    Plast Reconstr Surg; 2003 Sep 15; 112(4):1089-98. PubMed ID: 12973229
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
    Alster TS, Lupton JR.
    Dermatol Surg; 2003 May 15; 29(5):516-8. PubMed ID: 12752520
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H.
    Plast Reconstr Surg; 2015 Mar 15; 135(3):732-741. PubMed ID: 25719692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.